Eduard Jirkovsky

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9233816/publications.pdf

Version: 2024-02-01

25 papers	943 citations	777949 13 h-index	721071 23 g-index
27 all docs	27 docs citations	27 times ranked	1406 citing authors

#	Article	IF	Citations
1	Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up. Clinical Science, 2022, 136, 139-161.	1.8	1
2	The effects of bisphenols on the cardiovascular system. Critical Reviews in Toxicology, 2022, 52, 66-87.	1.9	12
3	Vitamin Câ€"Sources, Physiological Role, Kinetics, Deficiency, Use, Toxicity, and Determination. Nutrients, 2021, 13, 615.	1.7	150
4	Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin. Medicinal Research Reviews, 2021, 41, 2195-2246.	5.0	28
5	Structureâ€"Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIÎ² Interactions. Journal of Medicinal Chemistry, 2021, 64, 3997-4019.	2.9	14
6	Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circulation: Heart Failure, 2021, 14, e008209.	1.6	24
7	Silymarin Dehydroflavonolignans Chelate Zinc and Partially Inhibit Alcohol Dehydrogenase. Nutrients, 2021, 13, 4238.	1.7	9
8	Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIÎ²Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, 402-415.	1.3	14
9	Clearance of senescent cells during cardiac ischemiaâ€"reperfusion injury improves recovery. Aging Cell, 2020, 19, e13249.	3.0	79
10	In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline. Clinical Science, 2019, 133, 1827-1844.	1.8	10
11	79â€...Effective cardioprotection against anthracycline cardiotoxicity in isolated cardiomyocytes and rabbits is based on dexrazoxane interaction with topoisomerase II beta instead of iron chelation by its metabolite ADR-925. , 2019, , .		0
12	Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 433-446.	1.3	15
13	Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?. Toxicology, 2016, 372, 52-63.	2.0	1
14	Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. Journal of Molecular and Cellular Cardiology, 2016, 91, 92-103.	0.9	20
15	Cardiac troponinsâ€"Translational biomarkers in cardiology: Theory and practice of cardiac troponin highâ€sensitivity assays. BioFactors, 2016, 42, 133-148.	2.6	12
16	Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicology Research, 2015, 4, 1098-1114.	0.9	20
17	Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value. International Journal of Cardiology, 2015, 201, 358-367.	0.8	9
18	Molecular Remodeling of Left and Right Ventricular Myocardium in Chronic Anthracycline Cardiotoxicity and Post-Treatment Follow Up. PLoS ONE, 2014, 9, e96055.	1.1	38

#	Article	IF	Citations
19	Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology, 2013, 311, 191-204.	2.0	28
20	Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection. Antioxidants and Redox Signaling, 2013, 18, 899-929.	2.5	267
21	Chronic Anthracycline Cardiotoxicity: Molecular and Functional Analysis with Focus on Nuclear Factor Erythroid 2-Related Factor 2 and Mitochondrial Biogenesis Pathways. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 468-478.	1.3	48
22	Proteomic insights into chronic anthracycline cardiotoxicity. Journal of Molecular and Cellular Cardiology, 2011, 50, 849-862.	0.9	57
23	In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Archives of Toxicology, 2011, 85, 525-535.	1.9	24
24	Daunorubicin does not induce immunohistochemically detectable endothelial dysfunction in rabbit aorta and femoral artery. Histology and Histopathology, 2011, 26, 551-62.	0.5	0
25	Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical Research in Toxicology, 2010, 23, 1105-1114.	1.7	61